CN117987505A - 对atp结合位点进行突变的血管内皮抑制素突变体 - Google Patents

对atp结合位点进行突变的血管内皮抑制素突变体 Download PDF

Info

Publication number
CN117987505A
CN117987505A CN202410186085.0A CN202410186085A CN117987505A CN 117987505 A CN117987505 A CN 117987505A CN 202410186085 A CN202410186085 A CN 202410186085A CN 117987505 A CN117987505 A CN 117987505A
Authority
CN
China
Prior art keywords
mutant
vascular endothelial
seq
amino acid
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410186085.0A
Other languages
English (en)
Chinese (zh)
Inventor
罗永章
刘鹏
鲁薪安
陈阳
付彦
常国栋
周代福
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of CN117987505A publication Critical patent/CN117987505A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CN202410186085.0A 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体 Pending CN117987505A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201110280441 2011-09-09
CN2011102804418 2011-09-09
PCT/CN2012/081210 WO2013034116A1 (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体
CN201280078261.4A CN108291248B (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280078261.4A Division CN108291248B (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Publications (1)

Publication Number Publication Date
CN117987505A true CN117987505A (zh) 2024-05-07

Family

ID=47831548

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410186085.0A Pending CN117987505A (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体
CN201280078261.4A Active CN108291248B (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280078261.4A Active CN108291248B (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Country Status (9)

Country Link
US (1) US10647968B2 (cg-RX-API-DMAC7.html)
EP (1) EP2754718B1 (cg-RX-API-DMAC7.html)
JP (1) JP6336389B2 (cg-RX-API-DMAC7.html)
CN (2) CN117987505A (cg-RX-API-DMAC7.html)
AU (1) AU2012306826B2 (cg-RX-API-DMAC7.html)
CA (1) CA2848118C (cg-RX-API-DMAC7.html)
IL (1) IL231419A0 (cg-RX-API-DMAC7.html)
RU (1) RU2014113924A (cg-RX-API-DMAC7.html)
WO (1) WO2013034116A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926933B (zh) * 2014-03-19 2018-09-07 北京仁和天通生物科技有限公司 Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
CN107148277B (zh) * 2014-11-03 2022-03-22 清华大学 一种抑制脂肪细胞分化和胰岛素耐受的药物
JP6896636B2 (ja) * 2015-02-13 2021-06-30 清華大学Ｔｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ 組換えタンパク質薬の分子設計
CN110317264B (zh) * 2015-11-10 2022-10-11 孙嘉琳 一种抗肿瘤蛋白内皮抑素的衍生物
WO2018086603A1 (zh) * 2016-11-10 2018-05-17 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用
WO2019024814A1 (zh) * 2017-07-30 2019-02-07 清华大学 抑制dna依赖蛋白激酶催化亚基的药物
CN114645025B (zh) * 2022-04-13 2023-12-22 南开大学 一种人源atp合成酶的纯化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029856A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Restin and methods of use thereof
AU4982200A (en) * 1999-05-06 2000-11-21 Burnham Institute, The Antiangiogenic endostatin peptides, endostatin variants and methods of use
CN1237072C (zh) * 2000-05-22 2006-01-18 烟台荣昌生物工程有限公司 生产内皮抑制素的方法
JP4511108B2 (ja) * 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101143894A (zh) * 2007-06-22 2008-03-19 中国药科大学 高效抑制血管生成多肽及其物理化学修饰方法和应用
EP2270055A4 (en) * 2008-04-04 2011-06-29 Procell Therapeutics Inc CELLPERMEABLE RECOMBINANT ENDOSTATINE PROTEIN, POLYNUCLEOTIDE FOR ITS CODING AND ANTICIPATED PREPARATION WITH THE PROTEIN AS AN ACTIVE SUBSTANCE
CN101256139A (zh) * 2008-04-18 2008-09-03 山东先声麦得津生物制药有限公司 一种血管内皮抑制素生物活性的检测方法
CN101890155B (zh) * 2010-05-25 2012-07-25 江苏先声药物研究有限公司 一种药物组合物及其应用

Also Published As

Publication number Publication date
JP6336389B2 (ja) 2018-06-06
CN108291248B (zh) 2024-03-08
JP2014531897A (ja) 2014-12-04
IL231419A0 (en) 2014-04-30
AU2012306826B2 (en) 2018-01-04
EP2754718A1 (en) 2014-07-16
US20140308263A1 (en) 2014-10-16
AU2012306826A1 (en) 2014-04-03
WO2013034116A1 (zh) 2013-03-14
HK1251864A1 (zh) 2019-04-26
US20150197733A9 (en) 2015-07-16
CA2848118C (en) 2023-09-05
RU2014113924A (ru) 2015-10-20
CA2848118A1 (en) 2013-03-14
CN108291248A (zh) 2018-07-17
US10647968B2 (en) 2020-05-12
EP2754718B1 (en) 2017-12-13
EP2754718A4 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
CN108291248B (zh) 对atp结合位点进行突变的血管内皮抑制素突变体
CN100400657C (zh) 磷酸激酶及其应用
Capila et al. Annexin V–heparin oligosaccharide complex suggests heparan sulfate–mediated assembly on cell surfaces
JP2021534776A (ja) リコンビナントタンパク質変異体
US6391574B1 (en) AFC1 and RCE1: isoprenylated CAAX processing enzymes
CN101643511B (zh) 抑制端粒酶活性的融合蛋白、其制备及应用
KR930002832B1 (ko) 안기오게닌의 억제제
Chang et al. HRad17 colocalizes with NHP2L1 in the nucleolus and redistributes after UV irradiation
CN114957491B (zh) 一种靶向结合β-catenin蛋白的多肽、多肽衍生物及其应用
Zhao et al. Earthworm fibrinolytic enzyme
US20030064061A1 (en) Bcr-Abl oligomerization domain polypeptides and uses therefor
HK1194771A (en) Vascular endothelial myostatin mutant that mutates at atp binding sites
HK1194771B (en) Vascular endothelial myostatin mutant that mutates at atp binding sites
WO2023108666A1 (zh) 一类靶向covid-19病毒s蛋白的超高亲和力小蛋白及用途
KR20010103740A (ko) 포유류 세린 라세마제
CN1712542B (zh) 肝细胞癌相关的蛋白质分子标记原癌蛋白18的筛选及其应用
HK1251864B (en) Vascular endothelial myostatin mutant that mutates at atp binding sites
CN114848849B (zh) Pcsk9蛋白抑制剂在治疗心血管疾病中的应用
CN111808938A (zh) Atp6v0d2用于动脉粥样硬化的早期诊断或疗效监控
CN112442496A (zh) 精氨酸脱亚胺酶突变体及其应用
Zhang et al. Production of active pigment epithelium-derived factor in E. coli
JP4232423B2 (ja) 新規ユビキチン特異プロテアーゼ
Al Ameer Cloning, Protein Expression, and Characterization of Interleukin 1 Alpha
US20040072296A1 (en) AFC1 and RCE1: isoprenylated CAAX processing enzymes
WO2006070804A1 (ja) テロメレース活性阻害方法および阻害剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination